Estelle Berger-Marrer

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma.

Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma.

Journal: Clinical pharmacology and therapeutics

Published: March 07, 2026

Translational strategy to support the first-in-human study of a TCR-like T cell bispecific with an in vitro-based safety approach.

Translational strategy to support the first-in-human study of a TCR-like T cell bispecific with an in vitro-based safety approach.

Journal: Frontiers in immunology

Published: October 31, 2025

Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg-Depleting Antibody.

Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg-Depleting Antibody.

Journal: Clinical pharmacology and therapeutics

Published: February 16, 2024

Gut Microbiota Is Associated with Onset and Severity of Type 1 Diabetes in Nonobese Diabetic Mice Treated with Anti-PD-1.

Gut Microbiota Is Associated with Onset and Severity of Type 1 Diabetes in Nonobese Diabetic Mice Treated with Anti-PD-1.

Journal: ImmunoHorizons

Published: November 20, 2023

Immune-infiltrated kidney organoid-on-chip model for assessing T cell bispecific antibodies.

Immune-infiltrated kidney organoid-on-chip model for assessing T cell bispecific antibodies.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: August 21, 2023

The physiological interactome of TCR-like antibody therapeutics in human tissues.

The physiological interactome of TCR-like antibody therapeutics in human tissues.

Journal: Nature communications

Published: July 05, 2022

Patient-derived micro-organospheres enable clinical precision oncology.

Patient-derived micro-organospheres enable clinical precision oncology.

Journal: Cell stem cell

Published: September 16, 2021

Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.

Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.

Journal: Journal for immunotherapy of cancer

Published: July 05, 2021

CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.

CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.

Journal: Nature cancer

Published: March 01, 2021

Cytokine Release Syndrome By T-cell-Redirecting Therapies: Can We Predict and Modulate Patient Risk?

Cytokine Release Syndrome By T-cell-Redirecting Therapies: Can We Predict and Modulate Patient Risk?

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 28, 2021

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.

Journal: Blood

Published: December 22, 2020

Safety testing of monoclonal antibodies in non-human primates: Case studies highlighting their impact on human risk assessment.

Safety testing of monoclonal antibodies in non-human primates: Case studies highlighting their impact on human risk assessment.

Journal: mAbs

Published: October 10, 2017

Showing 1-12 of 12

Last Updated: 09/26/2026